Filtered By:
Specialty: Neurology
Drug: Pradaxa
This page shows you your search results in order of relevance. This is page number 9.
Order by Relevance | Date
Total 127 results found since Jan 2013.
Acute stroke thrombolysis following dabigatran reversal using idarucizumab
Kamble J Harsha, Sibi Thirunavukkarasu, Kenneth ButcherNeurology India 2019 67(2):568-570
Source: Neurology India - May 12, 2019 Category: Neurology Authors: Kamble J Harsha Sibi Thirunavukkarasu Kenneth Butcher Source Type: research
Safety and Efficacy of Dabigatran vs Warfarin After CVT
This randomized clinical trial conducted in 9 countries compares the use of dabigatran with warfarin in stroke prevention among patients who just experienced cerebral venous thrombosis.
Source: JAMA Neurology - September 3, 2019 Category: Neurology Source Type: research
Effects of Dabigatran in Mouse Models of Aging and Cerebral Amyloid Angiopathy
Oral anticoagulants are a critical component of stroke prevention, but carry a risk of brain hemorrhage. These hemorrhagic complications tend to occur in elderly individuals, especially those with predisposing conditions such as cerebral amyloid angiopathy (CAA). Clinical evidence suggests that non-vitamin K antagonist oral anticoagulants are safer than traditional oral anticoagulants. We analyzed whether the anticoagulant dabigatran produces cerebral microhemorrhage (the pathological substrate of MRI-demonstrable cerebral microbleeds) or intracerebral hemorrhage in aged mice with and without hemorrhage-predisposing angiop...
Source: Frontiers in Neurology - September 26, 2019 Category: Neurology Source Type: research
Reversal of anticoagulation effect of dabigatran with idarucizumab, for thrombolysis in acute ischemic stroke: Inimicus inimico amicus
Boby V Maramattom, Joe ThomasAnnals of Indian Academy of Neurology 2019 22(4):515-517
Source: Annals of Indian Academy of Neurology - October 24, 2019 Category: Neurology Authors: Boby V Maramattom Joe Thomas Source Type: research
Cerebral Venous Sinus Thrombosis and Acute Myocardial Infarction in a Patient with PAI-1 4G/4G Homozygosity
The plasminogen activator inhibitor-1 (PAI-1) 4G/4G homozygous genotype represents a genetic thrombophilia that has been associated with enhanced risk of arterial and venous thrombotic events. The optimal anticoagulation strategy for PAI-1 4G homozygous patients is unclear. Herein we present a case of a patient with PAI-1 4G/4G homozygosity who was placed on dabigatran after developing cerebral venous sinus thrombosis (CVST), but who then suffered an acute myocardial infarction several weeks later.
Source: Journal of Stroke and Cerebrovascular Diseases - August 25, 2020 Category: Neurology Authors: Daniel Chiu, Jesse Weinberger Tags: Case Report Source Type: research
Non-Vitamin K Antagonist Oral Anticoagulants for the Treatment of Cerebral Venous Sinus Thrombosis: a Retrospective, Matched Cohort Analysis
ConclusionsThe safety and efficacy results of NOAC use for CVT were similar to those for age-matched and sex-matched controls treated with VKAs, as well as historical published controls. Assessment of NOAC efficacy and safety in CVT in multicenter cohort studies and randomized controlled trials is warranted.
Source: Neurocritical Care - May 27, 2021 Category: Neurology Source Type: research
Left ventricular hypertrophy and left atrial size are associated with ischemic strokes among non-vitamin K antagonist oral anticoagulant users
ConclusionsPrior cerebrovascular events, diabetes, left ventricular hypertrophy, and increased left atrial size are risk factors for developing an IS among NOAC users.
Source: Journal of Neurology - August 7, 2023 Category: Neurology Source Type: research
